[
  {
    "symbol": "VKTX",
    "price": 15.51,
    "beta": 0.667605,
    "volAvg": 4188566,
    "mktCap": 1548509094,
    "lastDiv": 0,
    "range": "2.535-25.72",
    "changes": 0.675,
    "companyName": "Viking Therapeutics, Inc.",
    "currency": "USD",
    "cik": "0001607678",
    "isin": "US92686J1060",
    "cusip": "92686J106",
    "exchange": "NASDAQ Capital Market",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.vikingtherapeutics.com",
    "description": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.",
    "ceo": "Dr. Brian  Lian Ph.D.",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "22",
    "phone": "858 704 4660",
    "address": "9920 Pacific Heights Boulevard",
    "city": "San Diego",
    "state": "CA",
    "zip": "92121",
    "dcfDiff": 4.19675,
    "dcf": 4.37325,
    "image": "https://financialmodelingprep.com/image-stock/VKTX.png",
    "ipoDate": "2015-04-28",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]